JP2019011365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019011365A5 JP2019011365A5 JP2018192504A JP2018192504A JP2019011365A5 JP 2019011365 A5 JP2019011365 A5 JP 2019011365A5 JP 2018192504 A JP2018192504 A JP 2018192504A JP 2018192504 A JP2018192504 A JP 2018192504A JP 2019011365 A5 JP2019011365 A5 JP 2019011365A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- ars
- heterozygous mutation
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 32
- 201000011510 cancer Diseases 0.000 claims 28
- 238000000034 method Methods 0.000 claims 23
- 230000035772 mutation Effects 0.000 claims 22
- 239000003112 inhibitor Substances 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 101710165425 Alpha-enolase Proteins 0.000 claims 11
- 102100038910 Alpha-enolase Human genes 0.000 claims 11
- 101710184673 Enolase 1 Proteins 0.000 claims 11
- 238000011282 treatment Methods 0.000 claims 10
- 230000002414 glycolytic effect Effects 0.000 claims 9
- 230000004044 response Effects 0.000 claims 7
- 238000000338 in vitro Methods 0.000 claims 6
- 230000002349 favourable effect Effects 0.000 claims 5
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 claims 2
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims 2
- 238000011394 anticancer treatment Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 150000003384 small molecules Chemical group 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- OJCKRNPLOZHAOU-RSXXJMTFSA-N (1r,2r)-2-[(2s,4e,6e,8r,9s,11r,13s,15s,16s)-7-cyano-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6-dien-2-yl]cyclopentane-1-carboxylic acid Chemical compound O1C(=O)C[C@H](O)[C@@H](C)C[C@@H](C)C[C@@H](C)C[C@H](C)[C@@H](O)\C(C#N)=C\C=C\C[C@H]1[C@H]1[C@H](C(O)=O)CCC1 OJCKRNPLOZHAOU-RSXXJMTFSA-N 0.000 claims 1
- 102100037399 Alanine-tRNA ligase, cytoplasmic Human genes 0.000 claims 1
- OJCKRNPLOZHAOU-BNXNOGCYSA-N Borrelidin Natural products CC1CC(C)CC(C)C(O)C(=C/C=C/CC(OC(=O)CC(O)C(C)C1)C2CCCC2C(=O)O)C#N OJCKRNPLOZHAOU-BNXNOGCYSA-N 0.000 claims 1
- 230000007023 DNA restriction-modification system Effects 0.000 claims 1
- 238000001712 DNA sequencing Methods 0.000 claims 1
- 102100031004 Histidine-tRNA ligase, cytoplasmic Human genes 0.000 claims 1
- 101000879354 Homo sapiens Alanine-tRNA ligase, cytoplasmic Proteins 0.000 claims 1
- 101000843187 Homo sapiens Histidine-tRNA ligase, cytoplasmic Proteins 0.000 claims 1
- 101000875582 Homo sapiens Isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 claims 1
- 101000641003 Homo sapiens Tyrosine-tRNA ligase, cytoplasmic Proteins 0.000 claims 1
- 102100036015 Isoleucine-tRNA ligase, cytoplasmic Human genes 0.000 claims 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 claims 1
- 102100034298 Tyrosine-tRNA ligase, cytoplasmic Human genes 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 238000007899 nucleic acid hybridization Methods 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 239000000007 protein synthesis inhibitor Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000011269 tar Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570366P | 2011-12-14 | 2011-12-14 | |
| US61/570,366 | 2011-12-14 | ||
| US201261652738P | 2012-05-29 | 2012-05-29 | |
| US61/652,738 | 2012-05-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547490A Division JP6820653B2 (ja) | 2011-12-14 | 2012-12-14 | 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019011365A JP2019011365A (ja) | 2019-01-24 |
| JP2019011365A5 true JP2019011365A5 (https=) | 2019-04-25 |
| JP7193296B2 JP7193296B2 (ja) | 2022-12-20 |
Family
ID=48613367
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547490A Active JP6820653B2 (ja) | 2011-12-14 | 2012-12-14 | 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的 |
| JP2018192504A Active JP7193296B2 (ja) | 2011-12-14 | 2018-10-11 | 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547490A Active JP6820653B2 (ja) | 2011-12-14 | 2012-12-14 | 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9452182B2 (https=) |
| EP (2) | EP3603678A3 (https=) |
| JP (2) | JP6820653B2 (https=) |
| KR (2) | KR102144452B1 (https=) |
| CN (3) | CN115177727A (https=) |
| DK (1) | DK2790738T3 (https=) |
| ES (1) | ES2746058T3 (https=) |
| HR (1) | HRP20191607T1 (https=) |
| HU (1) | HUE045359T2 (https=) |
| IN (1) | IN2014DN05803A (https=) |
| WO (1) | WO2013090732A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015204452A1 (en) | 2014-01-13 | 2016-08-11 | Berg Llc | Enolase 1 (Eno1) compositions and uses thereof |
| CN104894229A (zh) * | 2014-03-04 | 2015-09-09 | 中南大学 | 己糖激酶2作为鼻咽癌放疗预后预测的生物标志物 |
| AU2014415566A1 (en) * | 2014-12-31 | 2017-07-20 | Develpment Center For Biotechnology | Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy |
| PT3268376T (pt) | 2015-03-09 | 2022-04-08 | Univ Texas | Inibidores de enolase e métodos de tratamento com os mesmos |
| EP3368687B1 (en) * | 2015-10-27 | 2021-09-29 | The Broad Institute, Inc. | Compositions and methods for targeting cancer-specific sequence variations |
| CA2937896A1 (en) * | 2016-08-02 | 2018-02-02 | Universite De Montreal | Use of mubritinib for the treatment of poor prognosis acute myeloid leukemia |
| CN107217054B (zh) * | 2017-04-25 | 2020-08-14 | 中山大学肿瘤防治中心 | G6pd基因及其表达产物在治疗结直肠癌中的应用 |
| CN107460250B (zh) * | 2017-09-28 | 2020-07-28 | 郑州大学第一附属医院 | 基于kif14、kif15和kif20a基因的透明细胞肾癌诊断试剂盒及其使用方法 |
| CN113573774B (zh) * | 2019-02-26 | 2026-03-06 | 诺沃库勒有限责任公司 | 基于靶向癌细胞的电特性确定TTfield治疗的频率 |
| MX2021011925A (es) * | 2019-03-29 | 2021-11-03 | Univ Texas | Compuestos con actividad antitumoral contra celulas cancerigenas que portan inserciones del exon 21 del receptor 2 del factor de crecimiento epidermico humano. |
| EP3976195A4 (en) * | 2019-05-28 | 2023-10-18 | The Regents Of The University Of California | METHODS OF TREATMENT OF SMALL CELL NEUROENDOCRINAL CANCERS AND ASSOCIATED CANCERS |
| EP4093513A4 (en) * | 2020-01-24 | 2024-05-08 | Dana-Farber Cancer Institute, Inc. | Uses of biomarkers for improving immunotherapy |
| CN113567675B (zh) * | 2020-04-28 | 2023-09-22 | 苏州浚惠生物科技有限公司 | 用于肿瘤的己糖激酶2抑制剂液体活检伴随诊断和试剂盒 |
| EP4225908A1 (en) * | 2020-10-06 | 2023-08-16 | European Molecular Biology Laboratory | Screening method for the identification of novel therapeutic compounds |
| WO2023089032A1 (en) * | 2021-11-19 | 2023-05-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
| WO2023239958A1 (en) * | 2022-06-10 | 2023-12-14 | The Children's Hospital Of Philadelphia | Alternatively spliced isoform in cancer and methods of use thereof |
| CN114751961B (zh) * | 2022-06-14 | 2022-09-20 | 中山大学孙逸仙纪念医院 | circ0005199-173aa蛋白及其在制备食管癌诊断产品中的应用 |
| CN115074445B (zh) * | 2022-08-09 | 2023-08-08 | 河北医科大学第二医院 | Eno3在肾癌诊断及治疗中的应用 |
| CN115825308B (zh) * | 2022-11-30 | 2023-06-09 | 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) | 鼻咽癌相关尿液标志物在制备用于鼻咽癌诊断/预后的产品中的应用 |
| CN116286828B (zh) * | 2023-05-12 | 2023-08-18 | 中国人民解放军军事科学院军事医学研究院 | 一种寡聚核酸siRNA及其在制备用于预防和治疗肝癌的药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5279721A (en) | 1993-04-22 | 1994-01-18 | Peter Schmid | Apparatus and method for an automated electrophoresis system |
| CA2283636A1 (en) * | 1997-03-20 | 1998-09-24 | Variagenics, Inc. | Target genes for allele-specific drugs |
| US6046002A (en) | 1998-01-05 | 2000-04-04 | The Board Of Trustees Of The Leland Stanford Junior University | Highly parallel and sensitive method for identifying drugs and drug targets |
| US6200754B1 (en) | 1998-03-19 | 2001-03-13 | Variagenics, Inc. | Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes |
| ATE408593T1 (de) | 2001-05-03 | 2008-10-15 | Galileo Lab Inc | Pyruvatderivate |
| WO2003082187A2 (en) * | 2002-03-26 | 2003-10-09 | Indiana University | Purification and cloning of nmn adenylyltranserase and its therapeutic use |
| ATE432097T1 (de) * | 2004-08-30 | 2009-06-15 | Interstitial Therapeutics | Medizinischer stent mit atp-synthesehemmern |
| CN101175862A (zh) | 2005-02-10 | 2008-05-07 | 肿瘤疗法科学股份有限公司 | 诊断膀胱癌的方法 |
| US20070077583A1 (en) * | 2005-09-21 | 2007-04-05 | Aurelium Biopharma, Inc. | Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance |
| US8193238B2 (en) | 2006-03-08 | 2012-06-05 | University Of Maryland, Baltimore | Inhibition of microtubule protrusion in cancer cells |
| US20100189648A1 (en) * | 2006-11-02 | 2010-07-29 | Lan Huang | Inhibitors for disrupting the interaction of ubiquitination related enzymes and uses thereof |
| TWI596109B (zh) | 2007-02-21 | 2017-08-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| WO2009002607A1 (en) * | 2007-05-01 | 2008-12-31 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identifying transforming and tumor suppressor genes |
| CN102225201A (zh) * | 2010-05-11 | 2011-10-26 | 中国医学科学院基础医学研究所 | 糖酵解抑制剂的新用途 |
-
2012
- 2012-12-14 IN IN5803DEN2014 patent/IN2014DN05803A/en unknown
- 2012-12-14 CN CN202210284955.9A patent/CN115177727A/zh active Pending
- 2012-12-14 KR KR1020147019549A patent/KR102144452B1/ko active Active
- 2012-12-14 HU HUE12858619A patent/HUE045359T2/hu unknown
- 2012-12-14 JP JP2014547490A patent/JP6820653B2/ja active Active
- 2012-12-14 EP EP19191479.5A patent/EP3603678A3/en active Pending
- 2012-12-14 CN CN201280069681.6A patent/CN104144707B/zh active Active
- 2012-12-14 DK DK12858619.5T patent/DK2790738T3/da active
- 2012-12-14 EP EP12858619.5A patent/EP2790738B1/en active Active
- 2012-12-14 WO PCT/US2012/069767 patent/WO2013090732A2/en not_active Ceased
- 2012-12-14 KR KR1020207022890A patent/KR102355121B1/ko active Active
- 2012-12-14 ES ES12858619T patent/ES2746058T3/es active Active
- 2012-12-14 HR HRP20191607 patent/HRP20191607T1/hr unknown
- 2012-12-14 US US14/365,367 patent/US9452182B2/en active Active
- 2012-12-14 CN CN201810965939.XA patent/CN109276717B/zh active Active
-
2018
- 2018-10-11 JP JP2018192504A patent/JP7193296B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019011365A5 (https=) | ||
| Bertucci et al. | PDL1 expression is an independent prognostic factor in localized GIST | |
| Winslow et al. | Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation and Haemophilus infection in COPD | |
| Metzeler et al. | ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category | |
| Weidner et al. | Aging of blood can be tracked by DNA methylation changes at just three CpG sites | |
| Huang et al. | MiR-155 is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO3 | |
| Fabbri et al. | Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia | |
| Kassem et al. | Merkel cell polyomavirus sequences are frequently detected in nonmelanoma skin cancer of immunosuppressed patients | |
| Yamada et al. | Identification of hypo-and hypermethylated genes related to atherosclerosis by a genome-wide analysis of DNA methylation | |
| Mullighan | How advanced are we in targeting novel subtypes of ALL? | |
| Teruel et al. | Epigenetic variability in systemic lupus erythematosus: what we learned from genome-wide DNA methylation studies | |
| Yadav et al. | Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas | |
| Pathak et al. | Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM | |
| Courtois et al. | IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition | |
| Hahtola et al. | Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma | |
| JP2015504041A5 (https=) | ||
| Fujiwara-Igarashi et al. | Inhibition of p16 tumor suppressor gene expression via promoter hypermethylation in canine lymphoid tumor cells | |
| Dai et al. | Genetic interactions between ANLN and KDR are prognostic for breast cancer survival | |
| Pastorczak et al. | Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment | |
| Carlsson et al. | The potential role of miR‑126, miR‑21 and miR‑10b as prognostic biomarkers in renal cell carcinoma | |
| Xu et al. | Epigenetically regulated lncRNAs dissect the intratumoural heterogeneity and facilitate immune evasion of glioblastomas | |
| Turkalj et al. | GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells | |
| Yu et al. | High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment | |
| Sayad et al. | Exploring the role of long non-coding RNAs in periodontitis | |
| Wang et al. | Associations between SOX2 and miR-200b expression with the clinicopathological characteristics and prognosis of patients with glioma |